Table 1.
Clinicopathologic features and treatment outcome of 22 Chinese patients with T-cell large granular lymphocyte leukemia
| Sex/age | Blood counts | Presentation | Comorbidities | Treatment | Current status | Molecular | Follow-up (months) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hb | ANC | LGL | Plat | No response | Response (time; months)a | outcome | |||||||
| 1 | M/44 | 5.4 | 4.8 | 4.6 | 186 | PRCA | HBV | CTX | FND × 6 (2) | CR for 1 year; relapsed, NR to CsA, CR after alemtuzumab, on CsA | CR | NR | 88+ |
| 2 | M/78 | 5.8 | 0.5 | 4.8 | 173 | PRCA | DM | - | FND × 6 (0) | PR; CR on CsA, no Rx now | CR | NR | 100+ |
| 3 | F/53 | 12.1 | 12.0 | 5.1 | 34 | HS, PN, Fever, ARDS | - | - | FND × 6 (0) | CR, no drugs, neuropathy recovered | CR | MR | 110+ |
| 4 | M/54 | 5.1 | 1.6 | 0.9 | 179 | HS, PRCA | HBV | CsA, CTX | FND × 3 (28) | PR; relapsed, CR with alemtuzumab, on CsA | CR | NR | 98+ |
| 5 | M/68 | 6.0 | 1.4 | 1.2 | 195 | PRCA | TB, CRF | CsA | FND × 1 (35) | CR × 1 year; relapsed | . | NR | |
| FND × 3 (55) | CR × 6 months; relapsed | Died of sepsis | MR | 37 | |||||||||
| 6 | M/50 | 8.5 | 1.2 | 2.1 | 256 | PN, PRCA | - | CsA | FND × 6 (44) | PR, neuropathy, CR with CsA | CR | MR | 110+ |
| 7 | M/46 | 4.7 | 1.3 | 2.0 | 161 | HS, PRCA | CRF | CsA | FND × 6 (59) | CR | CR | MR | 98+ |
| 8 | M/40 | 5.0 | 1.3 | 1.2 | 136 | HS, PRCA | HBV | CsA, CTX, ATG/CsA | FND × 3 (83) | PR; relapsed while on CsA, CR after alemtuzumab | CR | MR | 94+ |
| 9 | M/52 | 6.2 | 1.5 | 3.9 | 215 | PRCA | DM, TB, CRF | CsA, ATG, CTX, CLB | FND × 1 (84) | CR | Died of CVA | NR | 12 |
| 10 | M/71 | 9.8 | 1.8 | 10.2 | 66 | PRCA, S | Bladder CA | - | FND × 6 (0) | CR | Died of bladder CA | MR | 58 |
| 11 | F/43 | 8.9 | 1.1 | 7.4 | 431 | PRCA | - | - | FND × 6 (0) | CR | CR | NA | 63+ |
| 12 | F/41 | 8.7 | 0.8 | 5.1 | 490 | PRCA, S | - | - | FND × 6 (0) | CR | CR | MR | 39+ |
| 13 | M/21 | 5.3 | 3.5 | 14.2 | 166 | HS | Pul HT | CsA, CTX | FND × 2 (84) | PR, PR to alemtuzumab | Died of disease | NR | 36 |
| 14 | M/48 | 6.0 | 9.8 | 11.6 | 360 | PRCA | - | CsA, ATG, CTX,CLB, | - | Spontaneous remission for 8 years, relapsed, no Rx | Died of HCC | NA | 229 |
| 15 | M/39 | 9.9 | 4.6 | 18.5 | 83 | GVHD | CML, HSCT | - | - | - | Died of GVHD | NR | 10 |
| 16 | F/47 | 14.7 | 8.3 | 3.7 | 231 | ITP | - | - | CsA (14) | PR on CsA | PR | NR | 37+ |
| 17 | M/76 | 5.3 | 4.0 | 0.8 | 440 | PRCA | IHD | - | CsA (0) | CR | CR | NA | 33+ |
| 18 | M/46 | 9.1 | 2.6 | 0.8 | 258 | PRCA | - | - | CsA (0) | CR | CR | NA | 17+ |
| 19 | F/65 | 13.3 | 5.0 | 5.2 | 370 | - | IHD | - | - | Asymptomatic, no Rx | NR | NA | 32+ |
| 20 | F/84 | 5.0 | 4.4 | 1.5 | 444 | PRCA | - | - | CsA (0) | CR | CR | NA | 60+ |
| 21 | F/40 | 11.8 | 1.2 | 0.5 | 326 | - | - | - | - | Asymptomatic, no Rx | NR | NA | 24+ |
| 22 | F/44 | 11.5 | 1.7 | 1.2 | 85 | S | - | - | CsA (0) | PR | PR | NA | 3+ |
M male, F female, Hb hemoglobin (g/dL), ANC absolute neutrophil count (× 109/L), LGL large granular lymphocyte count (× 109/L), Plat platelet count (× 109/L), molecular molecular response judged by polymerase chain reaction for T-cell receptor gene, Rx therapy, FND fludarabine, mitoxantrone, dexamethasone, PRCA pure red cell aplasia, HBV hepatitis B virus, GVHD graft-versus-host disease, ITP immune thrombocytopenia purpura, CTX cyclophosphamide, CR complete remission, NR non-remission, PR partial remisson, CsA cyclosporin A, MR molecular remission, DM diabetes mellitus, HS hepatosplenomegaly, PN peripheral neuropathy, S splenomegaly, ATG anti-thymocyte globulin, ARDS adult respiratory distress syndrome, CRF chronic renal failure, CLB chlorambucil, CA carcinoma, NA not available, Pul HT pulmonary hypertension, CML chronic myeloid leukemia, HSCT hematopoietic stem cell transplantation, CVA cerebrovascular accident
aTime from presentation